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Purpose: The widespread use of 68Ga for positron emission tomography (PET) relies on the development of
radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner.
The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing
both cyclic and acyclic character that may allow for facile access to 68Ga-labelled tracers in the clinic. We report the
first bifunctional DATA chelator conjugated to [Tyr3]octreotide (TOC), a somatostatin subtype 2 receptor (SST2)-
targeting vector for imaging and functional characterisation of SSTR2 expressing tumours.
Methods: The radiopharmaceutical precursor, DATA-TOC, was synthesised as previously described and used to
complex natGa(III) and 68Ga(III). Competition binding assays of [natGa]Ga-DATA-TOC or [natGa]Ga-DOTA-TOC against
[125I-Tyr25]LTT-SS28 were conducted in membranes of HEK293 cells transfected to stably express one of the hSST2,3,5
receptor subtypes (HEK293-hSST2/3/5 cells). First in vivo studies were performed in female NMRI-nude mice bearing
SST2-positive mouse phaeochromocytoma mCherry (MPC-mCherry) tumours to compare the in vivo SST2-specific
tumour-targeting of [68Ga]Ga-DATA-TOC and its overall pharmacokinetics versus the [68Ga]Ga-DOTA-TOC reference.
A direct comparison of [68Ga]Ga-DATA-TOC with the well-established PET radiotracer [68Ga]Ga-DOTA-TOC was
additionally performed in a 46-year-old male patient with a well-differentiated NET (neuroendocrine tumour),
representing the first in human administration of [68Ga]Ga-DATA-TOC.
Results: DATA-TOC was labelled with 68Ga with a radiolabelling efficiency of > 95% in less than 10 min at ambient
temperature. A molar activity up to 35 MBq/nmol was achieved. The hSST2-affinities of [
natGa]Ga-DATA-TOC and
[natGa]Ga-DOTA-TOC were found similar with only sub-nanomolar differences in the respective IC50 values. In mice,
[68Ga]Ga-DATA-TOC was able to visualise the tumour lesions, showing standardised uptake values (SUVs) similar to
[68Ga]Ga-DOTA-TOC. Direct comparison of the two PET tracers in a NET patient revealed very similar tumour uptake
for the two 68Ga-radiotracers, but with a higher tumour-to-liver contrast for [68Ga]Ga-DATA-TOC.
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Conclusion: [68Ga]Ga-DATA-TOC was prepared, to a quality appropriate for in vivo use, following a highly efficient
kit type process. Furthermore, the novel radiopharmaceutical was comparable or better than [68Ga]Ga-DOTA-TOC in
all preclinical tests, achieving a higher tumour-to-liver contrast in a NET-patient. The results illustrate the potential of
the DATA-chelator to facilitate the access to and preparation of 68Ga-radiotracers in a routine clinical radiopharmacy
setting.
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There has been a surge in the development of 68Ga-radio-
pharmaceuticals over the last decade initiated by the clin-
ical and commercial success of [68Ga]Ga-DOTA-TOC
(TOC: DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-ol) and
[68Ga]Ga-DOTA-TATE (TATE: DPhe-c[Cys-Tyr-DTrp
-Lys-Thr-Cys]-Thr-OH), as well as by significant improve-
ments in the provision of 68Ga generators now fulfilling
pharmaceutical standards [1–6].
As a result, [68Ga]Ga-DOTA-TOC and [68Ga]Ga-DO-
TA-TATE are currently being used in clinical settings
for the diagnosis of neuroendocrine tumours (NETs).
Furthermore, [68Ga]Ga-DOTA-TATE acquired FDA ap-
proval as a diagnostic PET radiopharmaceutical for the
visualisation of NET lesions (FDA News Release, June 1,
2016), following the ‘orphan drug’ designation to
[68Ga]Ga-DOTA-TOC by FDA [7], and [68Ga]Ga-DO-
TA-TOC was approved by European Medicines Agency.
Due to the availability of 68Ga via commercial 68Ge/68Ga
generators and favourable emission characteristics for
PET imaging (β+ = 89%, Eβ,max = 1.9MeV), the facile and
efficient access to 68Ga-radiopharmaceuticals is expected
to drive the use of 68Ga in PET centres [1, 8–11]. A key
step in this direction is the development of simple, ef-
fective, robust, and reliable labelling protocols, which
depend primarily on the chelating moiety of the bifunc-
tional chelator (BFC) attached to the vector of interest.
Established BFCs based on a DOTA or DO3A scaffold
for 68Ga require relatively harsh conditions (a balance of
high temperatures, low pH, and high concentrations of
the precursor) for efficient radiolabelling [2, 12]. This re-
striction inherently limits the portfolio of 68Ga-radio-
pharmaceuticals, because several promising peptide-,
protein-, and antibody-based vectors for application in
nuclear oncology are temperature and/or pH sensitive
[13]. Thus, the radiolabelling of such molecules imposes
stringent requirements on the BFC, i.e. > 95% labelling
efficiency at ambient temperatures, less acidic condi-
tions, and at high molar activities. Moreover, in the case
of short-lived radionuclides, like 68Ga (t1/2 = 67.7 min),
shorter labelling times and simple preparations are
highly desirable, leading to a ready-for-injection radiola-
belled product that does not require further purification
prior to use. The development of such labellingprotocols should be seen as mandatory to fully exploit
the aforementioned advantages of 68Ga, but presents sig-
nificant challenges in the design of suitable BFCs [14].
In general, chelators (Additional file 1: Figure S1) can
be distinguished as cyclic (DOTA, NOTA, TRAP), asso-
ciated with high thermodynamic stability, or acyclic
(DFO, DTPA, HBED, THP), linked to a high kinetic sta-
bility that allows for higher labelling efficiency [12, 15–
19]. For example, Blower et al. demonstrated that THP
derivatives are superior in terms of labelling kinetics [20]
compared to BFCs with cyclic chelating functionalities
and the novel THP-conjugated radiopharmaceuticals are
under evaluation to prove their full viability in vivo for
different targeting vectors.
Special chelators like TRAP offer good properties in
general, but are predominantly seen in the context of
multivalent applications. The DATA scaffold represents
a unique approach to chelator design in that the chelat-
ing moiety is a hybrid, possessing both cyclic and acyclic
character. It is believed that flexibility of the acyclic por-
tion (6′ nitrogen and associated acetate function) facili-
tates rapid complexation, whilst the preorganised cyclic
portion minimises the energy barrier to complexation
and inhibits decomplexation processes [21, 22]. The
favourable radiolabelling kinetics of the DATA chelators,
ambient temperature, and pH 4–6.5, along with the
excellent stability of the forming 68Ga-chelates, justified
the development of a bifunctional derivative [23]. We
recently reported on the synthesis and 68Ga-radiola-
belling of the first DATA peptide conjugate,
DATA-TOC (Fig. 1) [23].
Following the promising results of the initial work
with uncoupled DATA-BFCs, the aim was to evaluate
the suitability of a DATA-BFC with an established vector
for comparison with the current clinical standard.
Therefore, [68Ga]Ga-DATA-TOC was selected as the
first target for comparison with [68Ga]Ga-DOTA-TOC
as the clinically established reference in a series of bio-
logical in vitro and in vivo models expressing the som-
atostatin subtype 2 receptor (hSST2), specifically (i)
competition binding assays in human SST2/3/5-positive
cell membranes, (ii) biodistribution and small animal
PET imaging in a preclinical mCherry-expressing mouse
phaeochromocytoma (MPC-mCherry) model with high
A B
Fig. 1 Structures of TOC coupled with a DATA and b DOTA. Chelator structures are highlighted
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tient previously diagnosed with NETs. This direct com-
parison will reveal the influence of a DOTA-to-DATA
chelator-switch on the biological behaviour of 68Ga-la-
belled DOTA-TOC.
Materials and methods
DATA-TOC was synthesised as previously described
[23], whilst DOTA-TOC was purchased from ABX
GmbH. The natGa complexes, [natGa]Ga-DATA-TOC
and [natGa]Ga-DOTA-TOC, were obtained after treat-
ment of the respective peptide conjugates with an excess
of natGaCl3 and subsequently purified by HPLC (Luna
10 μm (C18) 100 Å (250 mm × 10mm, 10 μm); A: H2O,
B: MeCN). The retention time (tR) of [
natGa]Ga-DOTA-
TOC and [natGa]Ga-DATA-TOC is 18.6 min and 19.9
min, respectively (linear gradient: 5% MeCN to 50%
MeCN in 20 min).
LTT-SS28 (H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-
Pro-Arg-Glu-Arg-Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-
DTrp-Lys-Thr-Tyr-Thr-Ser-Cys]-OH) was purchased
from Bachem.
Gallium-68 was eluted from one of two available
68Ge/68Ga generators (iThemba Labs) using 1.0M HCl.
The final HCl concentration of the eluates from both
generators was approximately 1M. The pH of the frac-
tionated 68Ga-eluate (300 μL containing 555MBq (15
mCi) 68Ga at the start of synthesis) was adjusted to pH
4.0–4.5 using 2.0 M NH4OAc. A solution of
68Ga(OAc)3
in acetate buffer was added to 20 nmol of each peptide.
The reaction mixture was shaken for 10 min at 80 °C to
afford [68Ga]Ga-DOTA-TOC or at 20 °C for 10 min to
afford [68Ga]Ga-DATA-TOC. Reaction mixtures were
analysed by radio-HPLC.Radio-HPLC was performed on a Series 1200 (Agilent)
HPLC equipped with the Ramona ß/γ-ray radiodetector
(Raytest): eluent A 0.1% (v/v) TFA in H2O; eluent B
0.1% (v/v) TFA in MeCN; HPLC system Zorbax (Agi-
lent) SB-C18, 300 Å, 4 μm, 250 mm × 9.4 mm; and linear
gradient elution using 95% eluent A to 95% eluent B in
10min, 50 °C. Radiolabelled products with radiochemical
purity higher than 95% were used for biological experi-
ments after filtering (45 μm pore size, REZIST 13/0.45
PTFE, Schleicher & Schuell) and diluting the labelling
reaction mixture. Filtrates were diluted with 0.1 mL elec-
trolyte solution E-153 (Serumwerk Bernburg AG) to a
final concentration of ~ 80MBq/mL [26, 27].
For the preparation of [125I-Tyr25]LTT-SS28, [125I]NaI
was provided by PerkinElmer in dilute sodium hydroxide
solution (pH 8–11) in an activity concentration of 13.52
GBq (365.4 mCi) per mL. Radioiodination was per-
formed according to the chloramine-T method using
0.1M D,L-methionine to quench the reaction, and the
radioligand was isolated by HPLC, as previously de-
scribed [28–30].Cell culture and in vitro assays
The HEK293 cell line was transfected to stably express
each of the hSST2/3/5 and the resultant HEK293-
hSST2/3/5 cells used for receptor affinity assessments
were donated by Prof. S. Schultz (Institute of Pharmacol-
ogy and Toxicology, University Hospital, Friedrich
Schiller University Jena, Germany). Cells were cultured
at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum, 100 U/mL
penicillin, 100 mg/mL streptomycin and 500 mg/mL
G418, as previously described [28, 30]. Culture reagents
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KG Seromed.
The genetically modified MPC-mCherry cells [25] de-
rived from MPC cells (clone 4/30PRR [31]) characterised
by a high density expression of mouse SST2 [24] were
cultured and prepared for in vivo application as previ-
ously described [24, 25].
Competition binding experiments were performed for
[natGa]Ga-DATA-TOC and [natGa]Ga-DOTA-TOC in
HEK293-hSST2/3/5 cell membranes, harvested as previ-
ously described [29]. [125I-Tyr25]LTT-SS28 served as
radioligand and LTT-SS28 ([Leu8,DTrp22,Tyr25]SS28) as
reference compound [28, 30, 32]. Briefly, radioligand
(70 μL, 50 pM corresponding to ≈ 40,000 cpm), test pep-
tide (30 μL solution of increasing concentrations, 10− 5
–10− 13 M), and membrane homogenates (200 μL) were
added to each assay tube (total volume of 300 μL in
binding solution: 50 mM HEPES pH 7.4, 1% BSA, 5.5
mM MgCl2, 35 μM bacitracin) in triplicates for each
concentration point. Samples were incubated for 60 min
at 22 °C in an Incubator-Orbital Shaker unit (MPM
Instr. SrI). Ice-cold washing buffer (10 mM HEPES pH
7.4, 150 mM NaCl) was added, followed by rapid filtra-
tion using glass fibre filters (Whatman GF/B, presoaked
for 2 h in a 1% polyethyleneimine (PEI) aqueous solu-
tion) on a Brandel Cell Harvester (Adi Hassel Ingenieur
Büro) washed with ice-cold washing buffer. Filters were
collected, and their activity measured in a γ-counter (au-
tomated well-type multisample gamma counter; NaI(Tl)
3″ crystal, Canberra Packard Auto-Gamma 5000 series
instrument). The half maximal inhibitory concentration
(IC50) values were calculated by nonlinear regression
according to a one-site model applying the PRISM 2
program (Graph Pad Software) and represent mean
IC50 ± sd from n experiments performed in triplicate for
[natGa]Ga-DATA-TOC (n = 3), [natGa]Ga-DOTA-TOC
(n = 2), and LTT-SS28 (n = 3).
Animal studies
A number of 2 × 106 MPC-mCherry cells were trans-
planted subcutaneously into the right shoulder of female
NMRI-nude mice (8 to 10 weeks old, RjOrl:NMRI-
Foxn1nu /Foxn1nu, Janvier Labs). Tumour growth was
monitored by fluorescence imaging using the in vivo
Xtreme optical imaging system (Bruker) [24] under an-
aesthesia that was induced and maintained by inhalation
of 12% and 9% (v/v) desflurane in 30/10% (v/v) oxygen/
air, respectively. Animals were studied when the tumour
diameter was 6 to 9 mm.
For biodistribution studies with [68Ga]Ga-DATA-TOC
17 (control n = 9, blocked n = 8) and [68Ga]Ga-DOTA-
TOC 12 (control n = 5, blocked n = 7) female mice (body
weight 36.3 ± 2.1 g) were injected intravenously into a
tail vein with approximately 2.3MBq (62 μCi)/0.35 nmolpeptide (DATA-TOC 11.2 nmol/kg body weight and
DOTA-TOC 10.5 nmol/kg body weight) in 0.1 mL elec-
trolyte solution E-153 (Serumwerk Bernburg AG) with-
out (control) or with simultaneous injection of 100 μg/
mouse [Nal3]octreotide acetate (blocked). Animals were
sacrificed at 60 min post-injection (p.i.). Blood, tumour,
and the major organs were collected, weighed, and
counted in a cross-calibrated γ-counter (Isomed 1000,
Isomed GmbH) and Wallac WIZARD Automatic
Gamma Counter (PerkinElmer). The activity of the tis-
sue samples was decay-corrected and calibrated by com-
paring the counts in tissue with the counts in aliquots of
the injected radiotracer that had been measured in the
γ-counter at the same time. The activity in the selected
organs was expressed as percent-injected activity per
organ (%IA) and the activity concentration in tissues and
organs as standardised uptake value (SUV in [MBq ac-
tivity/g tissue]/[MBq injected activity/g body weight]).
Values are quoted as mean ± standard deviation for each
group of animals.
PET scans were performed using a dedicated rodent
PET/CT scanner (NanoPET/CT, Mediso). Anaesthetised
mice (two animals per group) bearing subcutaneous
MPC-mCherry-tumours on the right shoulder were
positioned on a warmed bed along the scanner axis.
The 68Ga-labelled product, 10MBq/0.26 nmol/300 μL
(8.6 nmol DATA-TOC/kg body weight) and 10MBq/
0.26 nmol/300 μL (14.1 nmol DOTA-TOC/kg body
weight), was infused over 1 min into a tail vein. PET im-
ages were acquired beginning with the injection on a
Mediso NanoPET/CT camera and were reconstructed in
dynamic mode with 38 frames and 0.5 mm3 voxel size.
Total scan time was 2 h. Region-of-interest (ROI) quan-
tification was performed with ROVER (ABX GmbH).
The ROI values were not corrected for recovery and par-
tial volume effects. For each nanoPET/CT scan, 3D ROIs
were drawn over the tumour, heart, muscle, liver, and
kidneys in decay-corrected whole-body orthogonal
images.
Statistical analyses were carried out with GraphPad
Prism version 6 (GraphPad Software). The data
expressed as mean ± SEM was submitted to a one-way
analysis of variance (ANOVA) with post hoc Tukey’s
multiple comparisons test, with a single pooled variance.
Values of P < 0.05 were considered statistically significant
and indicated by an asterisk (*).
Human studies
A direct comparison between [68Ga]Ga-DATA-TOC and
[68Ga]Ga-DOTA-TOC was performed in a 46-year-old
male patient with well-differentiated NET lesions in the
body and tail of the pancreas as well as peritumoural
lymph node metastases, first diagnosed in November
2012. The large primary tumour involving the stomach,
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resected (R2) by distal pancreatectomy, partial gastrec-
tomy, splenectomy, left adrenalectomy, and omentect-
omy. Despite octreotide therapy, the disease was
progressing, and in 2015, the patient was treated with
peptide receptor radionuclide therapy (PRRT), adminis-
tering 5 GBq of [90Y]Y-DOTA-TOC. Before the second
cycle, restaging was performed on a Biograph mCT
FLOW 64 PET/CT from the vertex until mid-thigh
exactly 50 min after separate injections of 117MBq of
[68Ga]Ga-DOTA-TOC (~ 5 μg peptide) and 120MBq of
[68Ga]Ga-DATA-TOC (~ 5 μg peptide). The PET/CT
with [68Ga]Ga-DATA-TOC was performed 24 h after the
[68Ga]Ga-DOTA-TOC PET/CT. Written informed con-
sent was obtained from the patient in accordance with
paragraph 37 of the updated Declaration of Helsinki,
‘Unproven Interventions in Clinical Practice’, and in ac-
cordance with the German Medical Products Act AMG
§13 2b.
Results
Affinity of [natGa]Ga-DATA-TOC and [natGa]Ga-DOTA-TOC
for the hSST2/3/5
The metallated peptide conjugates [natGa]Ga-DATA-
TOC and [natGa]Ga-DOTA-TOC were tested for their
ability to displace the pansomatostatin radioligand
[125I-Tyr25]LTT-SS28 from hSST2/3/5-binding sites in
HEK293-hSST2/3/5 cell membranes using the pansoma-
tostatin ligand LTT-SS28 as reference [28–30]. As shown
in Fig. 2, both metallated octapeptide analogs exhibited
high affinity for the hSST2 ([
natGa]Ga-DATA-TOC, IC50
= 1.03 ± 0.08 nM, and [natGa]Ga-DOTA-TOC, IC50 =Fig. 2 Displacement of [125I-Tyr25]LTT-SS28 from hSST2 binding sites
in HEK293-hSST2 cell membranes by increasing concentrations of
the following: square, [natGa]Ga-DATA-TOC (IC50 = 1.03 ± 0.08 nM, n =
3); diamond, [natGa]Ga-DOTA-TOC (IC50 = 0.21 ± 0.01 nM, n = 2); and
control: asterisk, LTT-SS28 (IC50 = 0.05 ± 0.01 nM, n = 3). Results
represent the average IC50 values ± sd of independent experiments
performed in triplicate0.21 ± 0.01 nM). Compared to LTT-SS28 (IC50 = 0.05 ±
0.01 nM), both analogs were less affine, but absolute dif-
ferences in the respective IC50 values were rather small
[32]. It should be noted, that LTT-SS28 displayed
sub-nM affinity also for hSST3 (IC50 = 0.9 ± 0.01 nM)
and hSST5 (IC50 = 0.17 ± 0.03 nM). In contrast, [
natGa]-
Ga-DATA-TOC and [natGa]Ga-DOTA-TOC were found
to be hSST2 preferring (Additional file 1: Table S1).
Small animal PET and biodistribution
Micro-PET imaging: specific tumour binding
In dynamic PET studies in NMRI-nude mice, the im-
planted allogenic subcutaneous MPC-mCherry tumour
was clearly visible with both radiotracers. Figure 3 shows
coronal sections of dynamic PET images summarised
from 1 to 2 h p.i. (midframe time 90 min) for one animal
each. In vivo data for [68Ga]Ga-DATA-TOC and
[68Ga]Ga-DOTA-TOC are illustrated for one animal
each under A and C, respectively. For both radiotracers,
the micro-PET data show a high accumulation of the ra-
diotracers in the tumours. On a quantitative scale, the
SUV (given in Fig. 3) appears to be higher for [68Ga]Ga-
DOTA-TOC. However, the micro-PET data are affected
by photon energies of 68Ga, by partial volume and
spill-over effects. Accordingly, for a quantitative and sta-
tistically relevant comparison, we performed ex vivo
organ distributions with n = 9 animals, see below.
In addition to the absolute tumour uptake of the two
tracers it is important to address the specificity of the
binding. Figure 3 shows the in vivo data for [68Ga]Ga--
DATA-TOC and [68Ga]Ga-DOTA-TOC for the same
animal with the SST2 blocked by 100 μg/mouse [Nal
3]oc-
treotide acetate, charts B and D, respectively. Qualitatively,
both [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-TOC
demonstrated specific binding to the tumours which could
be blocked effectively. The quantitative degree of the
blocking study again was addressed by ex vivo organ dis-
tribution studies.
Concerning the kidneys visualised in Fig. 3, kidney up-
take is dependent in part on the individual hydration,
urine flow of the mouse, and level of the anaesthesia.
The figure shows individual mice at a specific time point
during the PET study. The accumulation of the radio-
tracers in the kidney may differ across mice and from
timepoint to timepoint. Consequently, kidney uptake is
also addressed in the ex vivo biodistribution studies.
Micro-PET imaging: kinetics of tumour binding
The in vivo PET studies allow kinetic data for the SUV
in several organs at different timepoints p.i. to be col-
lected. Figure 4 shows the ratios between tumour and
blood as SUVmean (tumour)/SUVmean (blood). The kin-
etic tumour-to-blood ratios of [68Ga]Ga-DATA-TOC and
[68Ga]Ga-DOTA-TOC show a similar linear shape. At 1 h
Fig. 3 Coronal sections of PET images summarised from 1 to 2 h p.i. (midframe time 90min), from dynamic PET studies of [68Ga]Ga-DATA-TOC (A,
B) and [68Ga]Ga-DOTA-TOC (C, D) distribution in MPC-mCherry tumour-bearing NMRI nu/nu mice after single intravenous injections of the
radiotracers as control (A, C) and blocked (B, D) by 100 μg/mouse [Nal3]octreotide acetate. The yellow arrows show the positions of the tumours
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SUR) of the control experiments with both compounds
reached similar levels of 31.6 ± 16.0 (n = 2) and 28.1 ± 1.3
(n = 3) for [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-
TOC, respectively. SUR values for the blocking study are
3.6 ± 0.0 (n = 2) and 2.7 ± 0.3 (n = 2) for [68Ga]Ga-DATA-
TOC and [68Ga]Ga-DOTA-TOC, respectively.
Ex vivo biodistribution: tumour binding
Biodistributions of [68Ga]Ga-DATA-TOC and [68Ga]Ga-
DOTA-TOC in subcutaneous MPC-mCherry tumour-
bearing mice were analysed at 1 h p.i. (Fig. 5, tabularFig. 4 Tumour-to-blood ratios of [68Ga]Ga-DATA-TOC and [68Ga]Ga-
DOTA-TOC calculated from dynamic PET studies with two animals
per group (values are mean ± SEM)results are presented in the Additional file 1 in Tables S2
and S3) for quantitative comparison of tumour accumula-
tion, distribution, and elimination in control and blocked
state. Figure 5a shows values of uptake in terms of %ID,
whilst Fig. 5b shows values in terms of SUV. Both graphs
also show ratios derived from the results of the blocking
studies.
The tumour uptake of [68Ga]Ga-DATA-TOC and
[68Ga]Ga-DOTA-TOC at 1 h after injection was in the
same range with SUVs of 3.41 ± 1.43 and 4.52 ± 1.96
(P = 0.2838), respectively. These quantitative and statisti-
cally relevant ex vivo data are consistent with the in vivo
PET data shown in Fig. 3.
Ex vivo biodistribution: specific tumour binding
The simultaneous injection of excess [Nal3]octreotide
clearly blocked the tumour accumulation for both radio-
tracers. The resulting activity concentrations were not
statistically significantly different with 0.36 ± 0.17 SUV
[68Ga]Ga-DATA-TOC and 0.26 ± 0.09 SUV [68Ga]Ga--
DOTA-TOC, P = 0.2145.
Ex vivo biodistribution: binding to other tissues
Blood and muscle: The blood concentration of
[68Ga]Ga-DATA-TOC (0.19 ± 0.08 SUV) was higher in
comparison to [68Ga]Ga-DOTA-TOC (0.06 ± 0.01 SUV;
P < 0.01). This resulted in a lower tumour-to-blood ratio
of 20.2 ± 11.9 vs. 70.5 ± 34.3; P < 0.01. However, the
tumour-to-muscle ratios for both radiotracers were not sta-
tistically different with 103.0 ± 57.2 for [68Ga]Ga-DATA-
TOC and 157.0 ± 34.6 for [68Ga]Ga-DOTA-TOC (P =
Fig. 5 Biodistribution of [68Ga]Ga-DATA-TOC and [68Ga]Ga-DOTA-TOC in selected organs and tissues expressed as a percent of injected activity
(%IA), b SUV in g/g, and c tumour-to-tissue ratios (SUV/SUV) 60 min after single intravenous injection of [68Ga]Ga-DATA-TOC (control n = 9,
blocked n = 8) and [68Ga]Ga-DOTA-TOC (control n = 5, blocked n = 7) in MPC-mCherry tumour-bearing NMRI-nude mice; blocked animals received
100 μg/mouse [Nal3]octreotide acetate together with the radiotracer
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at 1 h p.i. are graphically represented in Fig. 5c. This graph
also shows ratios derived from the results of the blocking
studies.
Pancreas: The pancreas expresses SST2 and was there-
fore investigated as well. Similar to the tumour, there
was a higher uptake of [68Ga]Ga-DOTA-TOC in the
pancreas with 0.84 ± 0.27 SUV compared to
[68Ga]Ga-DATA-TOC with 0.53 ± 0.15 SUV, P < 0.05.
The [Nal3]octreotide acetate injection decreased also
the accumulation of the [68Ga]Ga-DOTA-TOC in theFig. 6 [68Ga]Ga-DATA-TOC and [68Ga] Ga-DOTATOC PET/CT images. a [68Ga
TOC PET/CT images. c Transverse PET/CT fusion [68Ga]Ga-DOTA-TOC PET/C
in the primary pancreatic NET. The [68Ga]Ga-DATA-TOC PET/CT images sho
the [68Ga]Ga-DOTA-TOC PET/CT study in the same patient. There is significa
TOC in comparison with PET/CT images obtained after using [68Ga]Ga-DATpancreas from 0.836 ± 0.267 to 0.374 ± 0.268 SUV,
P < 0.05.
Patient study
Compared with [68Ga]Ga-DOTA-TOC PET/CT before
PRRT, post-PRRT [68Ga]Ga-DOTA-TOC PET/CT dem-
onstrated partial disease remission according to molecu-
lar imaging criteria (65% decrease of uptake in the
primary pancreatic tumour based on the
target-to-pituitary ratio). PET/CT with [68Ga]Ga-DA-
TA-TOC, performed 24 h later at the same time]Ga-DATA-TOC PET MIP. b Transverse PET/CT fusion of [68Ga]Ga-DATA-
T images. d [68Ga]Ga-DOTA-TOC PET MIP. Arrows indicate high uptake
w slightly higher physiological uptake in the kidneys as compared to
ntly higher uptake in normal liver after injection of [68Ga]Ga-DOTA-
A-TOC
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tense hSST2-uptake in the primary pancreatic tumour
(Fig. 6). There was a notable lower uptake of 68Ga]Ga-
DATA-TOC in normal liver (Table 1) compared to
[68Ga]Ga-DOTA-TOC.
Discussion
The novel TOC-conjugate, DATA-TOC, showed the po-
tential to establish an instant kit-type labelling routine of
clinically relevant vectors with 68Ga [23, 33]. To estab-
lish that the DATA chelator does not negatively affect
the receptor affinity and the in vivo performance of the
targeting vector, [68/natGa]Ga-DATA-TOC was directly
compared to [68/natGa]Ga-DOTA-TOC in a series of
in vitro and in vivo studies.
Radiolabelling with 68Ga for animal studies was com-
pleted quantitatively at 20 °C for DATA-TOC, whereas
for DOTA-TOC a higher temperature was required to
achieve comparable labelling efficiency. This finding cor-
roborates previously reported radiochemical data for
convenient and simple kit-type labelling of DATA-TOC
with 68Ga [23].
[natGa]Ga-DATA-TOC and [natGa]Ga-DOTA-TOC
showed high affinity for the hSST2. Although [
natGa]-
Ga-DOTA-TOC displayed fivefold higher affinity than
[natGa]Ga-DATA-TOC in this assay, absolute differences
in the pertinent IC50 values were < nM (Fig. 3). Based on
previous studies, such differences can be considered
minimal for clinical translation given that many other
critical factors (such as agonism or antagonism, stability,
pharmacokinetics, or tumour residence times) greatly
affect final clinical outcomes [28, 30, 34, 35]. Therefore,
it is reasonable to conclude that the exchange of DOTA
for the DATA chelator was well tolerated by the
hSST2-target. Furthermore, first in vivo small animal
PET studies comparing [68Ga]Ga-DATA-TOC to
[68Ga]Ga-DOTA-TOC showed similar biodistribution
and kinetic profiles. The uptake in the tumours was spe-
cific, reaching comparable values and following similar
kinetics. The tumour accumulation of both radiotracersTable 1 Comparison of SUVs between [68Ga]Ga-DATA-TOC and [68G
differentiated NET in the body and tail of the pancreas
Location SUV
[68Ga]
Target lesion 46.9
Liver 9.1
Ratio (target-to-liver) 5.2
Blood 2.7
Ratio (target-to-blood) 17.4
Pituitary 14.6
Ratio (target-to-pituitary gland) 3.2was blocked by [Nal3]octreotide acetate with similiar ac-
tivity concentration, suggesting an SST2-specific process.
Ex vivo organ distribution data was collected to mitigate
misleading micro-PET data that can be affected by pho-
ton energies of 68Ga, partial volume, and spill-over ef-
fects. Biodistribution of [68Ga]Ga-DATA-TOC and
[68Ga]Ga-DOTA-TOC in subcutaneous MPC-mCherry
tumour-bearing mice was analysed in terms of %IA and
in terms of SUV. The tumour uptake of both [68Ga]Ga-
DATA-TOC and [68Ga]Ga-DOTA-TOC at 1 h after in-
jection was in the same range with SUVs of 3.41 ± 1.43
and 4.52 ± 1.96 (P = 0.2838), respectively. The simultan-
eous injection of excess [Nal3]octreotide distinctly
blocked the tumour accumulation of both radiotracers.
These quantitative and statistically relevant ex vivo data
are in accordance to the in vivo small animal PET data.
The first in human comparison of [68Ga]Ga-DATA-
TOC and [68Ga]Ga-DOTA-TOC showed comparable
uptake in the tumour lesions. The SUVmax of the liver
in this patient on [68Ga]Ga-DOTA-TOC PET/CT was
higher than the previous value reported (23.1 vs 12.8 ±
3.6) [36]. However, in the head-to-head comparison, up-
take into the normal liver was significantly lower with
[68Ga]Ga-DATA-TOC than with [68Ga]Ga-DOTA-TOC
PET/CT (9.1 vs 23.1). Although [68Ga]Ga-DATA-TOC
resulted in a lower overall tumour uptake (SUV 46.9), a
significantly better tumour-to-liver ratio of 5.2 (com-
pared to 3.1 for [68Ga]Ga-DOTA-TOC) could be
achieved, which might enable better visualisation of liver
metastases [37].
The present study aimed to identify whether the new
chelator DATA influences the affinity and pharmacology
of the DATA-conjugated radiopharmaceutical [68Ga]Ga-
DATA-TOC relative to the industry standard [68Ga]Ga-
DOTA-TOC. The radiotracers displayed similar character-
istics in terms of in vitro affinity and in vitro internalisa-
tion to SST-positive cell lines, as well in terms of organ
distribution and uptake kinetics. [68Ga]Ga-DATA-TOC
displays high potential as a diagnostic agent in PET/CT,
whilst its ease of preparation adds an important aspect toa]Ga-DOTA-TOC in a 46-year-old male patient with a well-
Ga-DATA-TOC [68Ga]Ga-DOTA-TOC
71.1
23.1
3.1
2.0
35.6
23.7
3.0
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ation is an important advantage and applies also for some
other new chelators for 68Ga. THP and NOPO are two
such examples which have been conjugated to different
octreotide derivatives, specifically Tyr3-octreotate (TATE)
and NaI3-octreotide (NOC). [68Ga]Ga-THP-TATE was
synthesised and compared with [68Ga]Ga-DOTA-
TATE [38]. Head-to-head comparisons were performed in
terms of in vivo micro-PET imaging and ex vivo biodistri-
bution in Balb/c nu/nu mice bearing SST2-positive AR42J
tumours. Tumour uptake at 1 h p.i. showed that the up-
take of [68Ga]Ga-THP-TATE relative to [68Ga]Ga-DO-
TA-TATE was slightly lower (~ 20%), whilst kidney
retention was significantly higher. Liver accumulation and
blood retention were higher for [68Ga]Ga-THP-TATE.
Tumour-to-liver ratios obtained from PET images were
lower for [68Ga]Ga-THP-TATE (10.5) than for [68Ga]Ga-
DOTA-TATE (27.2). The differences were, in part,
attributed to significantly increased lipophilicity of
[68Ga]Ga-THP-TATE (almost five times more lipophilic
than [68Ga]Ga-DOTA-TATE). Indeed, a similar trend was
reported for another [68Ga]Ga-THP-conjugated radio-
pharmaceutical based on the RGD vector, namely
[68Ga]Ga-THP-NCS-RGD and [68Ga]Ga-THP-PhNCS-
RGD [39]. NOPO was attached to the octreotide deriva-
tive NaI3-octreotide (NOC), labelled with 68Ga and evalu-
ated in athymic CD-1 nude mice with AR42J tumours
using micro-PET imaging and ex vivo biodistribution [40].
Uptake of [68Ga]Ga-NOPO-NOC in the tumours was high
and specific, whilst uptake in other organs and tissue was
low with the exception of the kidneys.
It is not surprising that for the same molecular target-
ing vector (e.g. octreotide) and the radionuclide (e.g.
68Ga), the chelate will make a difference to the charac-
teristics of the resulting radiotracer. Therefore in the de-
velopment of new radiotracers, it is critical to quantify
and understand the impact any new chelate may have on
binding affinity, internalisation, organ distribution, up-
take kinetics, and excretion pathways of a certain type of
radiopharmaceutical in head-to-head assays. This will
demonstrate to what extent the ease of radiolabelling
demonstrated for a new group of chelators can be trans-
lated into clinical application, challenging the
state-of-the-art chelators such as DOTA and ultimately
to the benefit of patients.
Conclusion
It has been shown that [68Ga]Ga-DATA-TOC can be
prepared in a simple kit-type manner, and under milder
conditions than the DOTA-based counterpart. The de-
scribed small animal studies and first-in-human study
showed [68Ga]Ga-DATA-TOC equally able, and in some
cases slightly better, for the visualisation of NET lesions
compared to [68Ga]Ga-DOTA-TOC. Combining theseresults with the in vitro data, the chelator-switch from
DOTA to DATA did not negatively affect the biological
efficiency of the 68Ga-labelled TOC. Thus, this
proof-of-principle study demonstrated the practical ad-
vantages of DATA for instant kit-type labelling without
negatively affecting the efficacy.
These advantages highlight the potential of the DATA
chelator as a promising tool for 68Ga-radiolabelling in
general, but especially for radiolabelling of heat- and/or
pH-sensitive vectors. As a future perspective, the
instant-kit type labelling of DATA-based molecular vec-
tors will be broadened to include other medically inter-
esting molecules, such as antibody fragments.
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